Drew Doshier is a Principal at Bluestem Capital, where his responsibilities include the evaluation of prospective companies, deal structuring, and support of portfolio companies. He has been part of the investment team on all of Bluestem’s eye care investments, including Tear Film Innovations (acquired by Alcon), IanTECH (acquired by Carl Zeiss Meditec), Equinox Ophthalmic, TearClear, Lentechs, and others. He currently serves as a board observer at TearClear and Clarify Medical.
Prior to Bluestem, Drew worked at U.S. Bank where he helped promote the use of capital markets products within its Community Banking division. He holds a B.A. in Mathematics and Economics from Augustana University.